Core Viewpoint - The company, Buke Co., Ltd. (688160.SH), announced that its controlling shareholder, Shanghai Bujin, plans to reduce its shareholding due to personal funding needs, intending to sell up to 2.725 million shares, which represents no more than 3% of the company's total share capital [1] Summary by Relevant Sections - Shareholding Reduction Plan - The controlling shareholder, Shanghai Bujin, will reduce its holdings through centralized bidding and block trading [1] - The total number of shares to be sold is capped at 2.725 million [1] - This reduction accounts for a maximum of 3% of the company's total share capital [1]

Group 1 - The controlling shareholder, Hong Kong Junyao, reduced its stake in the company by 17.505 million shares, accounting for 1.5% of the total share capital [1] - The reduction took place between June 27, 2025, and July 4, 2025, through block trading [1] - The share price during the reduction ranged from 48.55 yuan to 51.19 yuan per share [1] Group 2 - After the completion of the reduction, Hong Kong Junyao and its concerted party, Zhongshan Hongting, hold a combined shareholding of 85.98%, down from 87.48% [1] - The change in shareholding percentage reached 1% [1]

Group 1 - The controlling shareholder Chengdu Local Construction Machinery Engineering Co., Ltd. and its concerted parties have reduced their shareholding in Huason Pharmaceutical Co., Ltd. from 70.00% to 68.76% through various trading methods [1][2] - A total of 5,193,650 shares were reduced, representing a decrease of 1.24% of the company's total share capital [1][2] - The shareholding structure post-reduction shows that Chengdu Local Construction and its concerted parties now hold 287,123,875 shares [1][2] Group 2 - The reduction of shares was executed in compliance with previously disclosed plans, and the total number of shares reduced is within the limits set by the reduction plan [2][3] - The reduction occurred between January 24, 2025, and June 9, 2025, with specific details on the number of shares sold through block trades and centralized bidding [1][2] - The announcement confirms that the information provided is accurate and complete, with no misleading statements or significant omissions [1]

Core Viewpoint - The controlling shareholder and actual controller of Yiming Pharmaceutical, Gao Fan, is planning to change the company's control, leading to a temporary suspension of the company's stock trading due to significant uncertainty surrounding the matter [1][3]. Group 1: Shareholder Information - Gao Fan, the founder of Yiming Pharmaceutical, holds 48.80 million shares, accounting for 25.59% of the total share capital, making him the largest shareholder [3]. - In September 2021, Gao Fan stepped down from his positions as chairman and general manager of the company but continued to hold a position in a subsidiary [3]. - Following his resignation, Gao Fan initiated a share reduction plan in June 2022, intending to reduce his holdings by up to 9.56 million shares (5% of total shares), but only reduced 635,800 shares (0.33%) by the end of the plan [4]. Group 2: Financial Performance - Yiming Pharmaceutical's revenue from 2020 to 2024 was as follows: 602.62 million, 725.46 million, 856.73 million, 667.04 million, and 651.88 million yuan, respectively, with net profits of 41.09 million, 43.47 million, 46.12 million, 15.73 million, and 47.46 million yuan [7]. - In 2023, the company experienced a 22.14% decline in revenue and a significant 65.9% drop in net profit [7]. - The company attributed the poor performance to changes in market conditions, industry environment, and underperformance of third-party cooperative products [8]. Group 3: Strategic Moves - Yiming Pharmaceutical had previously announced a private placement plan in April 2021, intending to raise between 200 million and 350 million yuan, but the plan was terminated four months later due to market conditions and business development considerations [6]. - The company acquired a 51% stake in Inner Mongolia Bostai Enterprise Management Service Co., Ltd. for 30.6 million yuan in August 2021, but the acquisition faced criticism due to the high premium paid [8].